Monoclonal Antibody against the Ectodomain of E-Cadherin (DECMA-1) Suppresses Breast Carcinogenesis: Involvement of the HER/PI3K/Akt/mTOR and IAP Pathways

PURPOSE: Although targeted therapies against HER2 have been one of the most successful therapeutic strategies for breast cancer, patients eventually developed acquired resistance from compensatory upregulation of alternate HERs and mitogen-activated protein kinase–phosphoinositide 3-kinase (PI3K)/Ak...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Brouxhon, Sabine M., Kyrkanides, Stephanos, Teng, Xiaofei, Raja, Veena, O’Banion, M. Kerry, Clarke, Robert, Byers, Stephen, Silberfeld, Andrew, Tornos, Carmen, Ma, Li
Format: Artigo
Langue:Inglês
Publié: 2013
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4014632/
https://ncbi.nlm.nih.gov/pubmed/23620408
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-2747
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires